157 related articles for article (PubMed ID: 21781649)
1. Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.
Bethke TD; Hartmann M; Hünnemeyer A; Lahu G; Gleiter CH
Int J Clin Pharmacol Ther; 2011 Aug; 49(8):491-9. PubMed ID: 21781649
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
[TBL] [Abstract][Full Text] [Related]
3. Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.
McCracken N; Lahu G; Bethke TD
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):388-96. PubMed ID: 21612746
[TBL] [Abstract][Full Text] [Related]
4. Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.
Hermann R; Nassr N; Lahu G; Péterfai E; Knoerzer D; Herzog R; Zech K; de Mey C
Clin Pharmacokinet; 2007; 46(5):403-16. PubMed ID: 17465639
[TBL] [Abstract][Full Text] [Related]
5. Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Huennemeyer A; Herzog R; McCracken N; Hermann R; Elmlinger M; Zech K
Int J Clin Pharmacol Ther; 2009 Apr; 47(4):236-45. PubMed ID: 19356389
[TBL] [Abstract][Full Text] [Related]
6. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A
J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871
[TBL] [Abstract][Full Text] [Related]
7. Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults.
Eckermann G; Lahu G; Nassr N; Bethke TD
J Clin Pharmacol; 2012 Feb; 52(2):251-7. PubMed ID: 21257799
[TBL] [Abstract][Full Text] [Related]
8. No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.
de Mey C; Nassr N; Lahu G
BMC Clin Pharmacol; 2011 Jun; 11():7. PubMed ID: 21631929
[TBL] [Abstract][Full Text] [Related]
9. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.
Bethke TD; Lahu G
Int J Clin Pharmacol Ther; 2011 Jan; 49(1):51-7. PubMed ID: 21176727
[TBL] [Abstract][Full Text] [Related]
10. Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.
Böhmer G; Gleiter CH; Hünnemeyer A; Lahu G; Bethke TD
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):451-60. PubMed ID: 21726496
[TBL] [Abstract][Full Text] [Related]
11. Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.
Lahu G; Huennemeyer A; von Richter O; Hermann R; Herzog R; McCracken N; Zech K
J Clin Pharmacol; 2008 Nov; 48(11):1339-49. PubMed ID: 18757786
[TBL] [Abstract][Full Text] [Related]
12. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
[TBL] [Abstract][Full Text] [Related]
13. Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.
von Richter O; Lahu G; Huennemeyer A; Herzog R; Zech K; Hermann R
Clin Pharmacokinet; 2007; 46(7):613-22. PubMed ID: 17596106
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pharmacokinetics of roflumilast in children and adolescents.
Neville KA; Szefler SJ; Abdel-Rahman SM; Lahu G; Zech K; Herzog R; Bethke TD; Gleason MC; Kearns GL
J Clin Pharmacol; 2008 Aug; 48(8):978-85. PubMed ID: 18508947
[TBL] [Abstract][Full Text] [Related]
15. Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.
Hauns B; Hermann R; Hünnemeyer A; Herzog R; Hauschke D; Zech K; Bethke TD
J Clin Pharmacol; 2006 Oct; 46(10):1146-53. PubMed ID: 16988203
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.
Li Q; Wang Y; Liu L; Ma P; Ding L
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):371-381. PubMed ID: 27306372
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.
Bethke TD; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Hauschke D; David M; Lahu G; Zech K; Hermann R; Siegmund W
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):572-9. PubMed ID: 17176624
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
19. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
